Melanoma is a type of skin cancer that starts when pigment cells in the skin grow uncontrollably, rising for the last 30 ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab ...

Researchers report good 10-year survival for people with melanoma and improvements for those with breast and bladder cancer.

A 10-year follow-up of the CheckMate 067 trial shows that around half of metastatic melanoma patients treated with nivolumab and ipilimumab are cancer-free after a decade. The study confirms long-term ...

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations ...

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or ...